Clinical Trials Sponsored by Regeneris Medical

Total 56010 results

Bayer
Regeneron Pharmaceuticals

Completed

Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan

Wet Macular Degeneration

Japan
Sanofi
Regeneron Pharmaceuticals

Completed

To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)

Rheumatoid Arthritis

United States, Argentina, Belgium, Brazil, Czechia, Estonia, Finland, Hungary, Israel, Italy, Mexico, Netherlands, Poland, Romania, Russian Federation, Spain, Sweden, United Kingdom, Norway
Sanofi
Regeneron Pharmaceuticals

Completed

To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis (SARIL-RA-EASY)

RA

United States, Chile, Mexico, Poland, Russian Federation, South Africa
Sanofi
Regeneron Pharmaceuticals

Completed

Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol

Hypercholesterolemia

United States
Sanofi
Regeneron Pharmaceuticals

Completed

A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan

Colorectal Cancer Metastatic

Japan
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan

Hypercholesterolemia

Japan
Sanofi
Regeneron Pharmaceuticals

Completed

Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects

Hypercholesterolemia

France
Sanofi
Regeneron Pharmaceuticals

Completed

Sarilumab Effect on the Pharmacokinetics of Simvastatin

Rheumatoid Arthritis

United States, Korea, Republic of, Moldova, Republic of
Sanofi
Regeneron Pharmaceuticals

Completed

Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Japan
Regeneron Pharmaceuticals
Sanofi

Completed

Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia

Sarcopenia

United States, Spain, Netherlands, France
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia

Hypercholesterolemia

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin

Hypercholesterolemia

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Ascending Dose Study of the Safety and Tolerability of REGN727 (SAR236553) in Healthy Volunteers

Healthy Volunteers

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Ascending Dose Study of the Safety and Tolerability of REGN727(SAR236553) in Healthy Volunteers

Healthy

United States
Sanofi
Regeneron Pharmaceuticals

Withdrawn

Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer (Drop and Go)

Colorectal Cancer Metastatic
Regeneron Pharmaceuticals
Sanofi

Completed

Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)

Healthy Volunteers

United States
Regeneron Pharmaceuticals
Bayer

Completed

DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact (DA VINCI)

Diabetic Macular Edema

United States, Austria, Canada
Bayer
Regeneron Pharmaceuticals

Completed

VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) (Myrror)

Myopia, Pathological

Japan, Taiwan, Hong Kong, Korea, Republic of, Singapore
Sanofi
Regeneron Pharmaceuticals

Completed

Comparison of the Pharmacokinetics and Safety of Two SAR231893 (REGN668) Drug Products in Healthy Subjects

Healthy

United States
Sanofi
Regeneron Pharmaceuticals

Completed

A Phase I Study of Intravenous Aflibercept in Combination With Docetaxel in Japanese Cancer Patients

Neoplasms

Japan
Regeneron Pharmaceuticals
Sanofi

Completed

A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Russian Federation
Regeneron Pharmaceuticals
Sanofi

Completed

Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786)

Healthy Volunteers

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)

Hypercholesterolemia

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects

Hypercholesterolemia

Moldova, Republic of, France
Sanofi
Regeneron Pharmaceuticals

Completed

Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects

Hypercholesterolemia

United States
Regeneron Pharmaceuticals
Bayer

Completed

Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD

Macular Degeneration

United States
Regeneron Pharmaceuticals
Bayer

Completed

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

Macular Edema Secondary to Central Retinal Vein Occlusion

United States, Canada, Colombia, Israel, India
Sanofi
Regeneron Pharmaceuticals

Completed

Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites

Ovarian Neoplasms | Ascites

United States, Canada, Spain, India, Belgium, Austria, Hungary, Israel, United Kingdom
Regeneron Pharmaceuticals
Sanofi

Completed

Ascending Dose Study of the Safety and Tolerability of REGN728 in Healthy Volunteers

Healthy

United States
Regeneron Pharmaceuticals
Sanofi

Completed

A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy Subjects

Healthy

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy Volunteers

Healthy

United States
Regeneron Pharmaceuticals
Bayer

Completed

Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)

Macular Degeneration

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients

Rheumatoid Arthritis

United States
Sanofi
Regeneron Pharmaceuticals

Completed

A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese Cancer Patients

Neoplasms

Japan
RegeneRx Biopharmaceuticals, Inc.

Withdrawn

A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction

ST Elevation Myocardial Infarction | Acute Myocardial Infarction | STEMI
Regenera Pharma Ltd

Terminated

Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Nonarteritic Anterior Ischemic Optic Neuropathy

United States
Regenera Pharma Ltd

Completed

Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).

Non-arteritic Ischemic Optic Neuropathy | Optic Nerve Injuries

Israel
Regenera Pharma Ltd

Withdrawn

Trial To Evaluate RPh201 In Treatment Of Partial Thickness Burn

Partial Thickness Burn | Second Degree Burn Less Than 5%TBSA

Israel
RegeneRx Biopharmaceuticals, Inc.

Completed

Study of Thymosin Beta 4 in Patients With Pressure Ulcers

Pressure Ulcers

United States
Duke University
Regeneron Pharmaceuticals

Recruiting

IL13 Signaling in Allergic Asthma

Obesity | Asthma | Asthma, Allergic

United States
Mayo Clinic
Regeneron Pharmaceuticals

Recruiting

Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus

Pruritus

United States
Northwestern University
Regeneron Pharmaceuticals

Completed

Gene Expression and Biomarker Profiling of Keloid Skin

Healthy Adults | Keloid | Keloid of Ear Lobe

United States
SillaJen, Inc.
Regeneron Pharmaceuticals

Active, not recruiting

A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma

Renal Cell Carcinoma

United States, Australia, Korea, Republic of
Stanford University
Regeneron Pharmaceuticals

Withdrawn

A Pharmacokinetic stuDy of intRavitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Diabetic Macular Edema (DRAW-2)

Diabetic Macular Edema

United States
Regeneron Pharmaceuticals
Alnylam Pharmaceuticals

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult Volunteers

Healthy

Belgium
Tennessee Retina
Regeneron Pharmaceuticals

Unknown

On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD) (ROLL)

Age Related Macular Degeneration | Pigment Epithelial Detachment

United States
Regenera Pharma Ltd

Completed

A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease

Mild to Moderate Dementia Due to Alzheimer's Disease | With or Without Coexisting Cerebrovascular Disease

Canada
RegeneRx Biopharmaceuticals, Inc.

Withdrawn

A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers

Myocardial Infarction | Myocardial Ischemia

United States
Duke University
Regeneron Pharmaceuticals

Not yet recruiting

TOP 2301: Neoadjuvant Chemo for NSCLC

Non Small Cell Lung Cancer

3

Subscribe